DelveInsight Highlights Major Advances, Transformative Therapies, and 6+ Leading Players Wheeling the Anal Cancer Clinical Trial Pipeline Landscape
The Anal Cancer Pipeline Insight 2023 report by DelveInsight offers a thorough global overview of Anal Cancer treatments, including those already in the market, as well as those in different phases of clinical development. Prominent pharmaceutical firms are dedicated to progressing the Anal Cancer pipeline landscape and fostering the potential growth of Anal Cancer therapeutic advancements.
Key Takeaways from the Anal Cancer Pipeline Report
- DelveInsight’s Anal Cancer pipeline report depicts a robust space with 6+ active players working to develop 6+ pipeline therapies for Anal Cancer treatment.
- The leading companies working in the Anal Cancer Market include Incyte Corporation, Merck & Co, Novartis Pharmaceuticals, Advaxis, Boehringer Ingelheim, Sumitomo Pharma Oncology Inc., Advaxis Inc., The Emmes Company LLC, BioMimetix JV LLC, Corregene Biotechnology Co. Ltd, Inovio Pharmaceuticals, Novartis, Hoffmann-La Roche, Genentech Inc., Amgen, and others.
- Promising Anal Cancer Pipeline Therapies in the various stages of development include Pembrolizumab, TP-1454 Monotherapy, Axalimogene Filolisbac, Cetuximab, Cisplatin, Fluorouracil, Cetuximab, Mitomycin C, 5-Fluoruracil, Radiotherapy, and others.
- On May 2023, Centre Hospitalier Universitaire de Besancon announced a study of Phase 2 Clinical Trials for Biopsy. Squamous cell carcinoma of the anus (SCCA) is a rare cancer, however its incidence is increasing worldwide. SCCA is mostly induced by human papillomavirus (HPV) infections (high-risk types such as HPV-16 and -18) and HPV-related oncoproteins (E6 and E7) are expressed in more than 90% of cases.
- On June 2023, Dana-Farber Cancer Institute announced a study of Phase 2 Clinical Trials for Pembrolizumab. This research study is a Phase II clinical trial. Phase II clinical trials test the safety and effectiveness of an investigational drug to learn whether the drug works in treating a specific disease. “Investigational” means that the drug is being studied.
Request a sample and discover the recent advances in Anal Cancer Treatment Drugs @ Anal Cancer Pipeline Report
The Anal Cancer pipeline report provides detailed profiles of pipeline assets, a comparative analysis of clinical and non-clinical stage Anal Cancer drugs, inactive and dormant assets, a comprehensive assessment of driving and restraining factors, and an assessment of opportunities and risks in the Anal Cancer clinical trial landscape.
Anal Cancer Overview
Anal cancer is a rare condition, although its incidence has been increasing over the past several decades, particularly in women. The majority of anal cancers are squamous cell cancers and are linked with human papillomavirus (HPV) infection.
Find out more about Anal Cancer Treatment Drugs @ Drugs for Anal Cancer Treatment
Anal Cancer Emerging Drugs Profile
- PDS0101: Merck & Co
- Avelumab: Merck KGaA
Anal Cancer Pipeline Therapeutics Assessment
There are approx. 6+ key companies which are developing the therapies for Anal Cancer. The Anal Cancer companies which have their Anal Cancer drug candidates in the most advanced stage, i.e. phase II include, Merck & Co.
Learn more about the emerging Anal Cancer Pipeline Therapies @ Anal Cancer Clinical Trials Assessment
Scope of the Anal Cancer Pipeline Report
- Coverage- Global
- Therapeutic Assessment by Product Type: Mono, Combination, Mono/Combination
- Therapeutic Assessment by Clinical Stages: Discovery, Pre-clinical, Phase I, Phase II, Phase III
- Anal Cancer Companies- Merck & Co, Novartis Pharmaceuticals, Advaxis, Boehringer Ingelheim, Sumitomo Pharma Oncology Inc., Advaxis Inc., The Emmes Company LLC, BioMimetix JV LLC, Corregene Biotechnology Co. Ltd, Inovio Pharmaceuticals, Novartis, Hoffmann-La Roche, Genentech Inc., Amgen, and others.
- Anal Cancer Pipeline Therapies- Pembrolizumab, TP-1454 Monotherapy, Axalimogene Filolisbac, Cetuximab, Cisplatin, Fluorouracil, Cetuximab, Mitomycin C, 5-Fluoruracil, Radiotherapy, and others.
Dive deep into rich insights for new drugs for Anal Cancer Treatment, Visit @ Anal Cancer Market Drivers and Barriers, and Future Perspective
Table of Content
- Introduction
- Executive Summary
- Anal Cancer: Overview
- Pipeline Therapeutics
- Therapeutic Assessment
- Anal Cancer– DelveInsight’s Analytical Perspective
- Late Stage Products (Phase III)
- Retifanlimab: Incyte Corporation
- Drug profiles in the detailed report…..
- Mid Stage Products (Phase II)
- PDS0101: Merck & Co
- Drug profiles in the detailed report…..
- Early Stage Products (Phase I)
- Drug Name: Company Name
- Drug profiles in the detailed report…..
- Preclinical and Discovery Stage Products
- Drug name: Company name
- Drug profiles in the detailed report…..
- Inactive Products
- Anal Cancer Key Companies
- Anal Cancer Key Products
- Anal Cancer- Unmet Needs
- Anal Cancer- Market Drivers and Barriers
- Anal Cancer- Future Perspectives and Conclusion
- Anal Cancer Analyst Views
- Anal Cancer Key Companies
- 27. Appendix
For further information on the Anal Cancer Pipeline therapeutics, reach out to Anal Cancer Unmet Needs and Analyst Views
About Us
DelveInsight is a leading healthcare-focused market research and consulting firm that provides clients with high-quality market intelligence and analysis to support informed business decisions. With a team of experienced industry experts and a deep understanding of the life sciences and healthcare sectors, we offer customized research solutions and insights to clients across the globe. Connect with us to get high-quality, accurate, and real-time intelligence to stay ahead of the growth curve.
Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Yash Bhardwaj
Email: Send Email
Phone: 9193216187
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: NV
Country: United States
Website: https://www.delveinsight.com/consulting
